Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $323,489.18 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Shannon Devers sold 3,977 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $81.34, for a total transaction of $323,489.18. Following the transaction, the executive vice president directly owned 22,541 shares in the company, valued at $1,833,484.94. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ionis Pharmaceuticals Stock Down 2.1%

IONS opened at $80.04 on Monday. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $23.95 and a fifty-two week high of $86.15. The firm has a market capitalization of $12.96 billion, a P/E ratio of -47.36 and a beta of 0.28. The company’s 50-day moving average is $79.44 and its 200 day moving average is $65.14. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.79 and a quick ratio of 2.78.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The firm had revenue of $156.72 million during the quarter, compared to analyst estimates of $131.75 million. During the same quarter last year, the business posted ($0.95) EPS. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. Research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IONS. Needham & Company LLC upped their price objective on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Leerink Partners boosted their price target on shares of Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. HC Wainwright raised their price objective on shares of Ionis Pharmaceuticals from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Piper Sandler lifted their price objective on shares of Ionis Pharmaceuticals from $70.00 to $77.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, TD Cowen reissued a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $86.45.

Key Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: EU approval for Dawnzera (hereditary angioedema) expands Ionis’ commercial footprint after the prior U.S. clearance, increasing potential revenue and reinforcing the drug’s global launch narrative. This regulatory milestone supports longer-term sales upside and de-risks a marketed asset. Ionis’ Dawnzera Gets EU Approval for Hereditary Angioedema
• Negative Sentiment: Multiple insiders filed sales of Ionis shares today (large aggregate volumes from senior staff), which can be interpreted as profit-taking or signal reduced insider conviction and may pressure the stock in the near term. Key filings reported include sales by Brett Monia (44,034 shares), Elizabeth Hougen (12,922), Patrick O’Neil (9,191), Eugene Schneider (9,302), C. Frank Bennett (8,977), Brian Birchler (8,480), Shannon Devers (8,353), and two earlier smaller transactions. These are sizeable individual dispositions and bear watching for follow-on selling or the stated reasons in the filings (e.g., diversification, tax, option exercises).
  Brett Monia Sells 44,034 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
  Elizabeth Hougen Sells 12,922 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
  Patrick O’neil Sells 9,191 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
  Eugene Schneider Sells 9,302 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
  C Frank Bennett Sells 8,977 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
  Brian Birchler Sells 8,480 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
  Shannon Devers Sells 8,353 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
  Kyle Jenne Sells 1,823 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
  Holly Kordasiewicz Sells 4,141 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Institutional Trading of Ionis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Steigerwald Gordon & Koch Inc. bought a new position in Ionis Pharmaceuticals in the 3rd quarter worth approximately $25,000. Golden State Wealth Management LLC lifted its position in shares of Ionis Pharmaceuticals by 198.4% during the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after acquiring an additional 250 shares in the last quarter. Mather Group LLC. bought a new position in shares of Ionis Pharmaceuticals in the third quarter worth $27,000. Allworth Financial LP raised its stake in shares of Ionis Pharmaceuticals by 231.8% during the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after purchasing an additional 517 shares during the period. Finally, Quarry LP purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $38,000. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.